A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Daratumumab (Primary) ; Venetoclax (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 03 Jul 2018 Planned End Date changed from 15 Apr 2023 to 2 Jul 2023.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 22 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top